Comparing the current results to its competitors, Sol Gel Technologies Ltd reported Revenue increase in the 4 quarter 2025 by 68.04 % year on year. The sales growth was above Sol Gel Technologies Ltd 's competitors' average revenue growth of 15.29 %, achieved in the same quarter.
Sol gel Technologies Ltd , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 36.52 %
Sol Gel Technologies Ltd 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical industry and faces competition related to the FDA's Section 505(b)(2) regulatory pathway, which may impact approval timelines and allow competitors to enter the market more quickly. Its product candidates include SGT-610, Twyneo, and Epsolay. SGT-610 is being developed for the prevention of basal cell carcinoma (BCC) in patients with Gorlin syndrome and has received orphan drug designation. Currently, no approved pharmacotherapies exist for this indication. If approved, SGT-610 would compete indirectly with procedural and surgical treatments such as excision and Mohs surgery, as well as systemic therapies used off-label in certain BCC cases. Clinical trials for these products were not conducted in direct comparison with leading competitor products or standard-of-care drugs, which may affect the reliability of efficacy comparisons.
Due to outstanding performance in Overall company, revenue grew by 68.04 % Sol gel Technologies Ltd improved its market share, to approximately 0.01 %.
July 25, 2024
Sol-Gel Technologies, an innovative pharmaceutical company, has recently announced the signing of six exclusive license agreements aimed at the commercialization of its dermatological products, TWYNEO and EPSOLAY, in Europe and South Africa. These agreements underscore the company s strategic efforts to expand its market presence and leverage partnerships for effective distribution in these regions.TWYNEO is a novel topical treatment combining a fixed-dose formulation of two established ingredients, designed to address acne vulgaris in patients aged 12 years and older. The product has shown efficacy in clinical trials, making it a potent option for patients seeking an effective therapeutic solution for the...
April 1, 2024
The pharmaceutical industry continues to witness groundbreaking advancements that change the landscape of medical treatments. In an exciting development, Sol-Gels Collaboration Partner has emerged as the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Zoryve Cream, a revolutionary dermatological treatment. This significant milestone promises to bring affordable and accessible solutions to patients suffering from various skin conditions. In this article, we delve deeper into the implications of this breakthrough and the potential impact it holds for both patients and the pharmaceutical industry.Background: Sol-Gels Collaboration Partner and Zoryve CreamSol-Gels Collaboration ...
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Sol gel Technologies Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sol gel Technologies Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
